FindTrial
Sign In

What would be the benefits if H2 blockers were used in allergic rhinitis

EFFICACY & SAFETY OF H2 BLOCKERS AS ADD ON THERAPY TO H1 ANTIHISTAMINICS IN ALLERGIC RHINITIS AN OPEN LABEL RANDOMISED CONTROL TRIAL IN A TERTAIRY CARE HOSPITAL OF NORTH EAST INDIA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/03/050870
Enrollment
340
Registered
2023-03-20
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J069- Acute upper respiratory infection,unspecified

Interventions

Intervention1: TABLET FAMOTIDINE 40MG: After randomization one group of participants shall receive Tab.Bilastine 20 mg, once daily for 14 days and another group of participants shall receive Tab.Famot

Sponsors

Prasenjit Das
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Consenting patients above the age of 18 years shall be taken up for the study.

Exclusion criteria

Exclusion criteria: Patient is suffering from perennial allergic rhinitis & also form other form of rhinitis like Vasomotor rhinitis. Those patients who have received any form of treatment for allergic rhinitis for last one month Patient receiving treatment for other Co-Morbid Condition like Hypertension, Ischemic Heart Disease, Diabetes Meletus, Chronic Renal Failure, Thyrotoxicosis, Hypothyroidism & receiving glucocorticoids or any other anti-inflammatory drug. Patient is having any other associated nasal condition like nasal polyp, tumor of nose, rhinosinusitis People whose profession include driving, pilots, operating heavy machine. Pregnant women & lactating mother shall also be excluded from our study. Diagnosed cases of allergic fungal rhinosinusitis (AFRS),shall be excluded from the study.

Design outcomes

Primary

MeasureTime frame
To determine and compare the efficacy of Bilastine alone and Bilastine added with Famotidine in cases of allergic rhinitis, by assessing the total nasal symptom score and total non-nasal symptom score at day 7 and day 14 of treatment To determine and compare the percentage of participants become symptom free in both the groups, at the end of 14th day or completion of treatment. Timepoint: and day 14 of treatment It shall be assesd at baseline day 7 and at day 14—

Secondary

MeasureTime frame
To determine the level of serum IgE and absolute eosinophil count at day 0 and day 14 in the participants. Timepoint: day 0 and day 14—

Countries

India

Contacts

Public ContactDebasis Ray

Agartala Goverment medical college

Prasenjitram@gmail.com8974756107

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026